Advertisement

Search Results

Advertisement



Your search for Alice Goodman matches 8 pages

Showing 1 - 8


leukemia

ASH 2014: High Hopes for AG-221 in Advanced Leukemia

Although the data are preliminary, single-agent AG-221 therapy targeted to the IDH2 mutation holds great promise as a nonchemotherapy approach for the treatment of advanced hematologic malignancies, including relapsed/refractory acute myelogenous leukemia (AML) and untreated AML. The findings were...

leukemia

ASH 2014: CD19-Directed CAR T-Cell Therapy Yields High Rate of Durable Remissions in Pediatric Acute Lymphoblastic Leukemia

As more experience is gained with the use of genetically engineered chimeric antigen receptor (CAR) T cells in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL), the data continue to be highly encouraging. To date, 36 of 39 pediatric ALL patients (92%) treated with...

leukemia

ASH 2014: Blinatumomab Achieves Complete Molecular Responses in Majority of B-Cell Leukemia Patients

Results from the international phase II BLAST study show that one cycle of blinatumomab (Blincyto) immunotherapy achieved complete minimal residual disease response in 78% of patients with precursor B-cell acute lymphoblastic leukemia (ALL). Complete minimal residual disease response was...

leukemia

Novel Agents IPI-145 and ABT-199 Show Encouraging Results in Phase I CLL Studies

Two novel agents—the small-molecule PI3K inhibitor IPI-145 and the Bcl-2 inhibitor ABT-199—show promising activity in chronic lymphocytic leukemia (CLL), according to two phase I studies presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstracts...

hematologic malignancies
leukemia

Obinutuzumab/Chlorambucil Superior to Rituximab/Chlorambucil as First-Line Treatment for Older CLL Patients With Comorbidities

Obinutuzumab (Gazyva) plus chlorambucil (Leukeran) was superior to rituximab (Rituximab) plus chlorambucil as first-line therapy in older chronic lymphocytic leukemia (CLL) patients with comorbidities, with an acceptable safety profile, according to final results of the phase III CLL11 trial....

hematologic malignancies
leukemia
lymphoma

Successful Chimeric Antigen Receptor–Expressing T-Cell Treatment Reported in Advanced Lymphomas

Development of autologous genetically engineered anti-CD19 chimeric antigen receptor (CAR)-expressing T cells holds promise in the treatment of hematologic malignancies. CAR T cells are being studied in adult and pediatric acute lymphocytic leukemias and in chronic lymphocytic leukemia, and...

leukemia

Vemurafenib Produces Rapid Responses in Hairy Cell Leukemia

Preliminary results of an ongoing clinical trial suggest that the BRAF inhibitor vemurafenib (Zelboraf)—indicated for the treatment of metastatic melanoma with BRAF V600E mutation—may have an important role in the treatment of hairy cell leukemia. The cornerstone of therapy for this...

hematologic malignancies
leukemia

NCCN: Practical Considerations in Selecting Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia

Although imatinib (Gleevec) is the initial therapy for chronic myeloid leukemia (CML), several second-generation tyrosine kinase inhibitors are now approved for the treatment of this disease. Michael Millenson, MD, of Fox Chase Cancer Center in Philadelphia, reviewed practical considerations in...

Advertisement

Advertisement



;
Advertisement